['HIV-ANTIVIRAL AGENTS: NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS (NNRTIS)', 'EFAVIRENZ * NEVIRAPINE', '\xe2\x86\x93 ETRAVIRINE', 'COMBINING TWO NNRTIS HAS NOT BEEN SHOWN TO BE BENEFICIAL. CONCOMITANT USE OF INTELENCE \xc2\xae WITH EFAVIRENZ OR NEVIRAPINE MAY CAUSE A SIGNIFICANT DECREASE IN THE PLASMA CONCENTRATIONS OF ETRAVIRINE AND LOSS OF THERAPEUTIC EFFECT OF INTELENCE \xc2\xae . INTELENCE \xc2\xae AND OTHER NNRTIS SHOULD NOT BE CO-ADMINISTERED.', 'DELAVIRDINE', '\xe2\x86\x91 ETRAVIRINE', 'COMBINING TWO NNRTIS HAS NOT BEEN SHOWN TO BE BENEFICIAL. INTELENCE \xc2\xae AND DELAVIRDINE SHOULD NOT BE CO-ADMINISTERED.', 'RILPIVIRINE', '\xe2\x86\x93 RILPIVIRINE \xe2\x86\x94 ETRAVIRINE', 'COMBINING TWO NNRTIS HAS NOT BEEN SHOWN TO BE BENEFICIAL. INTELENCE \xc2\xae AND RILPIVIRINE SHOULD NOT BE COADMINISTERED.', 'HIV-ANTIVIRAL AGENTS: PROTEASE INHIBITORS (PIS)', 'ATAZANAVIR (WITHOUT RITONAVIR)', '\xe2\x86\x93 ATAZANAVIR', 'CONCOMITANT USE OF INTELENCE \xc2\xae WITH ATAZANAVIR WITHOUT LOW-DOSE RITONAVIR MAY CAUSE A SIGNIFICANT ALTERATION IN THE PLASMA CONCENTRATION OF ATAZANAVIR. INTELENCE \xc2\xae SHOULD NOT BE CO-ADMINISTERED WITH ATAZANAVIR WITHOUT LOW-DOSE RITONAVIR.', 'ATAZANAVIR/RITONAVIR', '\xe2\x86\x93 ATAZANAVIR \xe2\x86\x91 ETRAVIRINE', 'CONCOMITANT USE OF INTELENCE \xc2\xae WITH ATAZANAVIR/RITONAVIR MAY CAUSE A SIGNIFICANT DECREASE IN ATAZANAVIR C MIN AND LOSS OF THERAPEUTIC EFFECT OF ATAZANAVIR. IN ADDITION, THE MEAN SYSTEMIC EXPOSURE (AUC) OF ETRAVIRINE AFTER CO-ADMINISTRATION OF INTELENCE \xc2\xae WITH ATAZANAVIR/RITONAVIR IS ANTICIPATED TO BE HIGHER THAN THE MEAN SYSTEMIC EXPOSURE OF ETRAVIRINE OBSERVED IN THE PHASE 3 TRIALS AFTER CO-ADMINISTRATION OF INTELENCE \xc2\xae AND DARUNAVIR/RITONAVIR (AS PART OF THE BACKGROUND REGIMEN). INTELENCE \xc2\xae AND ATAZANAVIR/RITONAVIR SHOULD NOT BE CO-ADMINISTERED.', 'DARUNAVIR/RITONAVIR', '\xe2\x86\x93 ETRAVIRINE', 'THE MEAN SYSTEMIC EXPOSURE (AUC) OF ETRAVIRINE WAS REDUCED WHEN INTELENCE \xc2\xae WAS CO-ADMINISTERED WITH DARUNAVIR/RITONAVIR. BECAUSE ALL SUBJECTS IN THE PHASE 3 TRIALS RECEIVED DARUNAVIR/RITONAVIR AS PART OF THE BACKGROUND REGIMEN AND ETRAVIRINE EXPOSURES FROM THESE TRIALS WERE DETERMINED TO BE SAFE AND EFFECTIVE, INTELENCE \xc2\xae AND DARUNAVIR/RITONAVIR CAN BE CO-ADMINISTERED WITHOUT DOSE ADJUSTMENTS.', 'FOSAMPRENAVIR (WITHOUT RITONAVIR)', '\xe2\x86\x91 AMPRENAVIR', 'CONCOMITANT USE OF INTELENCE \xc2\xae WITH FOSAMPRENAVIR WITHOUT LOW-DOSE RITONAVIR MAY CAUSE A SIGNIFICANT ALTERATION IN THE PLASMA CONCENTRATION OF AMPRENAVIR. INTELENCE \xc2\xae SHOULD NOT BE CO-ADMINISTERED WITH FOSAMPRENAVIR WITHOUT LOW-DOSE RITONAVIR.', 'FOSAMPRENAVIR/RITONAVIR', '\xe2\x86\x91 AMPRENAVIR', 'DUE TO A SIGNIFICANT INCREASE IN THE SYSTEMIC EXPOSURE OF AMPRENAVIR, THE APPROPRIATE DOSES OF THE COMBINATION OF INTELENCE \xc2\xae AND FOSAMPRENAVIR/RITONAVIR HAVE NOT BEEN ESTABLISHED. INTELENCE \xc2\xae AND FOSAMPRENAVIR/RITONAVIR SHOULD NOT BE CO-ADMINISTERED.', 'INDINAVIR (WITHOUT RITONAVIR)', '\xe2\x86\x93 INDINAVIR', 'CONCOMITANT USE OF INTELENCE \xc2\xae WITH INDINAVIR WITHOUT LOW-DOSE RITONAVIR MAY CAUSE A SIGNIFICANT ALTERATION IN THE PLASMA CONCENTRATION OF INDINAVIR. INTELENCE \xc2\xae SHOULD NOT BE CO-ADMINISTERED WITH INDINAVIR WITHOUT LOW-DOSE RITONAVIR.', 'LOPINAVIR/RITONAVIR', '\xe2\x86\x93 ETRAVIRINE', 'THE MEAN SYSTEMIC EXPOSURE (AUC) OF ETRAVIRINE WAS REDUCED AFTER CO-ADMINISTRATION OF INTELENCE \xc2\xae WITH LOPINAVIR/RITONAVIR (TABLET). BECAUSE THE REDUCTION IN THE MEAN SYSTEMIC EXPOSURES OF ETRAVIRINE IN THE PRESENCE OF LOPINAVIR/RITONAVIR IS SIMILAR TO THE REDUCTION IN MEAN SYSTEMIC EXPOSURES OF ETRAVIRINE IN THE PRESENCE OF DARUNAVIR/RITONAVIR, INTELENCE \xc2\xae AND LOPINAVIR/RITONAVIR CAN BE CO-ADMINISTERED WITHOUT DOSE ADJUSTMENTS.', 'NELFINAVIR (WITHOUT RITONAVIR)', '\xe2\x86\x91 NELFINAVIR', 'CONCOMITANT USE OF INTELENCE \xc2\xae WITH NELFINAVIR WITHOUT LOW-DOSE RITONAVIR MAY CAUSE A SIGNIFICANT ALTERATION IN THE PLASMA CONCENTRATION OF NELFINAVIR. INTELENCE \xc2\xae SHOULD NOT BE CO-ADMINISTERED WITH NELFINAVIR WITHOUT LOW-DOSE RITONAVIR.', 'RITONAVIR', '\xe2\x86\x93 ETRAVIRINE', 'CONCOMITANT USE OF INTELENCE \xc2\xae WITH RITONAVIR 600 MG TWICE DAILY MAY CAUSE A SIGNIFICANT DECREASE IN THE PLASMA CONCENTRATION OF ETRAVIRINE AND LOSS OF THERAPEUTIC EFFECT OF INTELENCE \xc2\xae . INTELENCE \xc2\xae AND RITONAVIR 600 MG TWICE DAILY SHOULD NOT BE CO-ADMINISTERED.', 'SAQUINAVIR/RITONAVIR', '\xe2\x86\x93 ETRAVIRINE', 'THE MEAN SYSTEMIC EXPOSURE (AUC) OF ETRAVIRINE WAS REDUCED WHEN INTELENCE \xc2\xae WAS CO-ADMINISTERED WITH SAQUINAVIR/RITONAVIR. BECAUSE THE REDUCTION IN THE MEAN SYSTEMIC EXPOSURES OF ETRAVIRINE IN THE PRESENCE OF SAQUINAVIR/RITONAVIR IS SIMILAR TO THE REDUCTION IN MEAN SYSTEMIC EXPOSURES OF ETRAVIRINE IN THE PRESENCE OF DARUNAVIR/RITONAVIR, INTELENCE \xc2\xae AND SAQUINAVIR/RITONAVIR CAN BE CO-ADMINISTERED WITHOUT DOSE ADJUSTMENTS.', 'TIPRANAVIR/RITONAVIR', '\xe2\x86\x93 ETRAVIRINE', 'CONCOMITANT USE OF INTELENCE \xc2\xae WITH TIPRANAVIR/RITONAVIR MAY CAUSE A SIGNIFICANT DECREASE IN THE PLASMA CONCENTRATIONS OF ETRAVIRINE AND LOSS OF THERAPEUTIC EFFECT OF INTELENCE \xc2\xae . INTELENCE \xc2\xae AND TIPRANAVIR/RITONAVIR SHOULD NOT BE CO-ADMINISTERED.', 'CCR5 ANTAGONISTS', 'MARAVIROC', '\xe2\x86\x94 ETRAVIRINE \xe2\x86\x93 MARAVIROC', 'WHEN INTELENCE \xc2\xae IS CO-ADMINISTERED WITH MARAVIROC IN THE ABSENCE OF A POTENT CYP3A INHIBITOR (E.G., RITONAVIR BOOSTED PROTEASE INHIBITOR), THE RECOMMENDED DOSE OF MARAVIROC IS 600 MG TWICE DAILY. NO DOSE ADJUSTMENT OF INTELENCE \xc2\xae IS NEEDED.', 'MARAVIROC/DARUNAVIR/RITONAVIR \xe2\x80\xa0', '\xe2\x86\x94 ETRAVIRINE \xe2\x86\x91 MARAVIROC', 'WHEN INTELENCE \xc2\xae IS CO-ADMINISTERED WITH MARAVIROC IN THE PRESENCE OF A POTENT CYP3A INHIBITOR (E.G., RITONAVIR BOOSTED PROTEASE INHIBITOR), THE RECOMMENDED DOSE OF MARAVIROC IS 150 MG TWICE DAILY. NO DOSE ADJUSTMENT OF INTELENCE \xc2\xae IS NEEDED.', 'OTHER AGENTS', 'ANTIARRHYTHMICS : DIGOXIN', '\xe2\x86\x94 ETRAVIRINE \xe2\x86\x91 DIGOXIN', 'FOR PATIENTS WHO ARE INITIATING A COMBINATION OF INTELENCE \xc2\xae AND DIGOXIN, THE LOWEST DOSE OF DIGOXIN SHOULD INITIALLY BE PRESCRIBED. FOR PATIENTS ON A STABLE DIGOXIN REGIMEN AND INITIATING INTELENCE \xc2\xae , NO DOSE ADJUSTMENT OF EITHER INTELENCE \xc2\xae OR DIGOXIN IS NEEDED. THE SERUM DIGOXIN CONCENTRATIONS SHOULD BE MONITORED AND USED FOR TITRATION OF THE DIGOXIN DOSE TO OBTAIN THE DESIRED CLINICAL EFFECT.', 'AMIODARONE, BEPRIDIL, DISOPYRAMIDE, FLECAINIDE, LIDOCAINE (SYSTEMIC), MEXILETINE, PROPAFENONE, QUINIDINE', '\xe2\x86\x93 ANTIARRHYTHMICS', 'CONCENTRATIONS OF THESE ANTIARRHYTHMICS MAY BE DECREASED WHEN CO-ADMINISTERED WITH INTELENCE \xc2\xae . INTELENCE \xc2\xae AND ANTIARRHYTHMICS SHOULD BE CO-ADMINISTERED WITH CAUTION. DRUG CONCENTRATION MONITORING IS RECOMMENDED, IF AVAILABLE.', 'ANTICOAGULANTS : WARFARIN', '\xe2\x86\x91 ANTICOAGULANTS', 'WARFARIN CONCENTRATIONS MAY BE INCREASED WHEN CO-ADMINISTERED WITH INTELENCE \xc2\xae . THE INTERNATIONAL NORMALIZED RATIO (INR) SHOULD BE MONITORED WHEN WARFARIN IS COMBINED WITH INTELENCE \xc2\xae .', 'ANTICONVULSANTS : CARBAMAZEPINE, PHENOBARBITAL, PHENYTOIN', '\xe2\x86\x93 ETRAVIRINE', 'CARBAMAZEPINE, PHENOBARBITAL AND PHENYTOIN ARE INDUCERS OF CYP450 ENZYMES. INTELENCE \xc2\xae SHOULD NOT BE USED IN COMBINATION WITH CARBAMAZEPINE, PHENOBARBITAL, OR PHENYTOIN AS CO-ADMINISTRATION MAY CAUSE SIGNIFICANT DECREASES IN ETRAVIRINE PLASMA CONCENTRATIONS AND LOSS OF THERAPEUTIC EFFECT OF INTELENCE \xc2\xae .', 'ANTIFUNGALS : FLUCONAZOLE , VORICONAZOLE', '\xe2\x86\x91 ETRAVIRINE \xe2\x86\x94 FLUCONAZOLE \xe2\x86\x91 VORICONAZOLE', 'CO-ADMINISTRATION OF ETRAVIRINE AND FLUCONAZOLE SIGNIFICANTLY INCREASED ETRAVIRINE EXPOSURES. THE AMOUNT OF SAFETY DATA AT THESE INCREASED ETRAVIRINE EXPOSURES IS LIMITED, THEREFORE, ETRAVIRINE AND FLUCONAZOLE SHOULD BE CO-ADMINISTERED WITH CAUTION. NO DOSE ADJUSTMENT OF INTELENCE \xc2\xae OR FLUCONAZOLE IS NEEDED.', '', '', 'CO-ADMINISTRATION OF ETRAVIRINE AND VORICONAZOLE SIGNIFICANTLY INCREASED ETRAVIRINE EXPOSURES. THE AMOUNT OF SAFETY DATA AT THESE INCREASED ETRAVIRINE EXPOSURES IS LIMITED, THEREFORE, ETRAVIRINE AND VORICONAZOLE SHOULD BE CO-ADMINISTERED WITH CAUTION. NO DOSE ADJUSTMENT OF INTELENCE \xc2\xae OR VORICONAZOLE IS NEEDED.', 'ANTIFUNGALS : ITRACONAZOLE, KETOCONAZOLE, POSACONAZOLE', '\xe2\x86\x91 ETRAVIRINE \xe2\x86\x93 ITRACONAZOLE \xe2\x86\x93 KETOCONAZOLE \xe2\x86\x94 POSACONAZOLE', 'POSACONAZOLE, A POTENT INHIBITOR OF CYP3A4, MAY INCREASE PLASMA CONCENTRATIONS OF ETRAVIRINE. ITRACONAZOLE AND KETOCONAZOLE ARE POTENT INHIBITORS AS WELL AS SUBSTRATES OF CYP3A4. CONCOMITANT SYSTEMIC USE OF ITRACONAZOLE OR KETOCONAZOLE AND INTELENCE \xc2\xae MAY INCREASE PLASMA CONCENTRATIONS OF ETRAVIRINE. SIMULTANEOUSLY, PLASMA CONCENTRATIONS OF ITRACONAZOLE OR KETOCONAZOLE MAY BE DECREASED BY INTELENCE \xc2\xae . DOSE ADJUSTMENTS FOR ITRACONAZOLE, KETOCONAZOLE OR POSACONAZOLE MAY BE NECESSARY DEPENDING ON THE OTHER CO-ADMINISTERED DRUGS.', 'ANTIINFECTIVES : CLARITHROMYCIN', '\xe2\x86\x91 ETRAVIRINE \xe2\x86\x93 CLARITHROMYCIN \xe2\x86\x91 14-OH-CLARITHROMYCIN', 'CLARITHROMYCIN EXPOSURE WAS DECREASED BY INTELENCE \xc2\xae ; HOWEVER, CONCENTRATIONS OF THE ACTIVE METABOLITE, 14-HYDROXY-CLARITHROMYCIN, WERE INCREASED. BECAUSE 14-HYDROXY-CLARITHROMYCIN HAS REDUCED ACTIVITY AGAINST MYCOBACTERIUM AVIUM COMPLEX (MAC), OVERALL ACTIVITY AGAINST THIS PATHOGEN MAY BE ALTERED. ALTERNATIVES TO CLARITHROMYCIN, SUCH AS AZITHROMYCIN, SHOULD BE CONSIDERED FOR THE TREATMENT OF MAC.', 'ANTIMALARIALS : ARTEMETHER/LUMEFANTRINE', '\xe2\x86\x94 ETRAVIRINE \xe2\x86\x93 ARTEMETHER \xe2\x86\x93 DIHYDROARTEMISININ \xe2\x86\x93 LUMEFANTRINE', 'CAUTION IS WARRANTED WHEN CO-ADMINISTERING INTELENCE\xc2\xae AND ARTEMETHER/LUMEFANTRINE AS IT IS UNKNOWN WHETHER THE DECREASE IN EXPOSURE OF ARTEMETHER OR ITS ACTIVE METABOLITE, DIHYDROARTEMISININ, COULD RESULT IN DECREASED ANTIMALARIAL EFFICACY. NO DOSE ADJUSTMENT IS NEEDED FOR INTELENCE \xc2\xae .', 'ANTIMYCOBACTERIALS: RIFAMPIN, RIFAPENTINE', '\xe2\x86\x93 ETRAVIRINE', 'RIFAMPIN AND RIFAPENTINE ARE POTENT INDUCERS OF CYP450 ENZYMES. INTELENCE \xc2\xae SHOULD NOT BE USED WITH RIFAMPIN OR RIFAPENTINE AS CO-ADMINISTRATION MAY CAUSE SIGNIFICANT DECREASES IN ETRAVIRINE PLASMA CONCENTRATIONS AND LOSS OF THERAPEUTIC EFFECT OF INTELENCE \xc2\xae .', 'ANTIMYCOBACTERIALS: RIFABUTIN', '\xe2\x86\x93 ETRAVIRINE \xe2\x86\x93 RIFABUTIN \xe2\x86\x93 25- O -DESACETYLRIFABUTIN', 'IF INTELENCE \xc2\xae IS NOT CO-ADMINISTERED WITH A PROTEASE INHIBITOR/RITONAVIR, THEN RIFABUTIN AT A DOSE OF 300 MG ONCE DAILY IS RECOMMENDED. IF INTELENCE \xc2\xae IS CO-ADMINISTERED WITH DARUNAVIR/RITONAVIR, LOPINAVIR/RITONAVIR OR SAQUINAVIR/RITONAVIR, THEN RIFABUTIN SHOULD NOT BE CO-ADMINISTERED DUE TO THE POTENTIAL FOR SIGNIFICANT REDUCTIONS IN ETRAVIRINE EXPOSURE.', 'BENZODIAZEPINES: DIAZEPAM', '\xe2\x86\x91 DIAZEPAM', 'CONCOMITANT USE OF INTELENCE \xc2\xae WITH DIAZEPAM MAY INCREASE PLASMA CONCENTRATIONS OF DIAZEPAM. A DECREASE IN DIAZEPAM DOSE MAY BE NEEDED.', 'CORTICOSTEROIDS : DEXAMETHASONE (SYSTEMIC)', '\xe2\x86\x93 ETRAVIRINE', 'SYSTEMIC DEXAMETHASONE INDUCES CYP3A AND CAN DECREASE ETRAVIRINE PLASMA CONCENTRATIONS. THIS MAY RESULT IN LOSS OF THERAPEUTIC EFFECT OF INTELENCE \xc2\xae . SYSTEMIC DEXAMETHASONE SHOULD BE USED WITH CAUTION OR ALTERNATIVES SHOULD BE CONSIDERED, PARTICULARLY FOR LONG-TERM USE.', "HERBAL PRODUCTS : ST. JOHN'S WORT ( HYPERICUM PERFORATUM )", '\xe2\x86\x93 ETRAVIRINE', "CONCOMITANT USE OF INTELENCE \xc2\xae WITH PRODUCTS CONTAINING ST. JOHN'S WORT MAY CAUSE SIGNIFICANT DECREASES IN ETRAVIRINE PLASMA CONCENTRATIONS AND LOSS OF THERAPEUTIC EFFECT OF INTELENCE \xc2\xae . INTELENCE \xc2\xae AND PRODUCTS CONTAINING ST. JOHN'S WORT SHOULD NOT BE CO-ADMINISTERED.", 'HEPATITIS C VIRUS (HCV) DIRECT-ACTING ANTIVIRALS : TELAPREVIR', '\xe2\x86\x94 ETRAVIRINE \xe2\x86\x93 TELAPREVIR', 'THERE ARE INSUFFICIENT DATA TO MAKE A DOSING RECOMMENDATION FOR TELAPREVIR WHEN USED WITH INTELENCE \xc2\xae .', 'HMG-COA REDUCTASE INHIBITORS : ATORVASTATIN FLUVASTATIN, LOVASTATIN, PITAVASTATIN, PRAVASTATIN, ROSUVASTATIN, SIMVASTATIN', '\xe2\x86\x94 ETRAVIRINE \xe2\x86\x93 ATORVASTATIN \xe2\x86\x91 2-OH-ATORVASTATIN \xe2\x86\x94 ETRAVIRINE \xe2\x86\x91 FLUVASTATIN, \xe2\x86\x93 LOVASTATIN, \xe2\x86\x91 PITAVASTATIN, \xe2\x86\x94 PRAVASTATIN, \xe2\x86\x94 ROSUVASTATIN, \xe2\x86\x93 SIMVASTATIN', 'THE COMBINATION OF INTELENCE \xc2\xae AND ATORVASTATIN CAN BE GIVEN WITHOUT DOSE ADJUSTMENTS, HOWEVER, THE DOSE OF ATORVASTATIN MAY NEED TO BE ALTERED BASED ON CLINICAL RESPONSE. NO INTERACTION BETWEEN PRAVASTATIN, ROSUVASTATIN AND INTELENCE \xc2\xae IS EXPECTED. LOVASTATIN AND SIMVASTATIN ARE CYP3A SUBSTRATES AND CO-ADMINISTRATION WITH INTELENCE \xc2\xae MAY RESULT IN LOWER PLASMA CONCENTRATIONS OF THE HMG-COA REDUCTASE INHIBITOR. FLUVASTATIN AND PITAVASTATIN ARE METABOLIZED BY CYP2C9 AND CO-ADMINISTRATION WITH INTELENCE \xc2\xae MAY RESULT IN HIGHER PLASMA CONCENTRATIONS OF THE HMG-COA REDUCTASE INHIBITOR. DOSE ADJUSTMENTS FOR THESE HMG-COA REDUCTASE INHIBITORS MAY BE NECESSARY.', 'IMMUNOSUPPRESSANTS : CYCLOSPORINE, SIROLIMUS, TACROLIMUS', '\xe2\x86\x93 IMMUNOSUPPRESSANT', 'INTELENCE \xc2\xae AND SYSTEMIC IMMUNOSUPPRESSANTS SHOULD BE CO-ADMINISTERED WITH CAUTION BECAUSE PLASMA CONCENTRATIONS OF CYCLOSPORINE, SIROLIMUS, OR TACROLIMUS MAY BE AFFECTED.', 'NARCOTIC ANALGESICS/TREATMENT OF OPIOID DEPENDENCE : BUPRENORPHINE, BUPRENORPHINE/NALOXONE , METHADONE', '\xe2\x86\x94 ETRAVIRINE \xe2\x86\x93 BUPRENORPHINE \xe2\x86\x94 NORBUPRENORPHINE \xe2\x86\x94 METHADONE', 'INTELENCE \xc2\xae AND BUPRENORPHINE (OR BUPRENORPHINE/NALOXONE) CAN BE CO-ADMINISTERED WITHOUT DOSE ADJUSTMENTS, HOWEVER, CLINICAL MONITORING FOR WITHDRAWAL SYMPTOMS IS RECOMMENDED AS BUPRENORPHINE (OR BUPRENORPHINE/NALOXONE) MAINTENANCE THERAPY MAY NEED TO BE ADJUSTED IN SOME PATIENTS. INTELENCE \xc2\xae AND METHADONE CAN BE CO-ADMINISTERED WITHOUT DOSE ADJUSTMENTS, HOWEVER, CLINICAL MONITORING FOR WITHDRAWAL SYMPTOMS IS RECOMMENDED AS METHADONE MAINTENANCE THERAPY MAY NEED TO BE ADJUSTED IN SOME PATIENTS.', 'PHOSPHODIESTERASE TYPE 5 (PDE-5) INHIBITORS : SILDENAFIL , TADALAFIL, VARDENAFIL', '\xe2\x86\x93 SILDENAFIL \xe2\x86\x93 N-DESMETHYL-SILDENAFIL', 'INTELENCE \xc2\xae AND SILDENAFIL CAN BE CO-ADMINISTERED WITHOUT DOSE ADJUSTMENTS, HOWEVER, THE DOSE OF SILDENAFIL MAY NEED TO BE ALTERED BASED ON CLINICAL EFFECT.', 'PLATELET AGGREGATION INHIBITORS: CLOPIDOGREL', '\xe2\x86\x93 CLOPIDOGREL (ACTIVE) METABOLITE', 'ACTIVATION OF CLOPIDOGREL TO ITS ACTIVE METABOLITE MAY BE DECREASED WHEN CLOPIDOGREL IS CO-ADMINISTERED WITH INTELENCE \xc2\xae . ALTERNATIVES TO CLOPIDOGREL SHOULD BE CONSIDERED.']